Published on Sep 22, 2016
Tom
Piotrowski speaks with Opthea (OPT) CEO & Managing Director, Megan
Baldwin about the results of its Phase 2 study of its OPT-302 drug aimed
at treating the Wet AMD eye disease.
Welcome to the new Opthea Twitter— Opthea (@Opthea1) December 19, 2012
No comments:
Post a Comment